Cartesian Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:1S70 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
14 Jan 25	Buy€355,876	Timothy Springer	Individual	20,967	€17.49
06 Jan 25	Sell€128,996	Blaine Davis	Individual	7,989	€16.20
06 Jan 25	Sell€29,016	Emily English	Individual	1,797	€16.20
06 Jan 25	Sell€41,174	Chris Jewell	Individual	2,550	€16.20
06 Jan 25	Sell€30,356	Milos Miljkovic	Individual	1,880	€16.20
06 Jan 25	Sell€78,715	Metin Kurtoglu	Individual	4,875	€16.20
06 Jan 25	Sell€278,869	Carsten Brunn	Individual	17,271	€16.20
23 Dec 24	Buy€928,157	Timothy Springer	Individual	52,189	€18.27
18 Nov 24	Buy€6,976,094	Timothy Springer	Individual	431,940	€17.43
04 Oct 24	Buy€3,916,572	Timothy Springer	Individual	205,721	€21.83
12 Aug 24	Buy€87,106	Timothy Barabe	Individual	7,500	€11.61
12 Aug 24	Buy€93,249	Timothy Springer	Individual	8,016	€11.63
18 Mar 24	Buy€10,484	Timothy Springer	Individual	634.8	€16.52
18 Mar 24	Buy€449	Timothy Springer	Individual	26.67	€16.83
15 Mar 24	Buy€10,060	Timothy Springer	Individual	586.67	€19.01
15 Mar 24	Buy€611,858	Timothy Springer	Individual	39,529.03	€16.12

Insider Trading Volume

Insider Buying: 1S70 insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1S70?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	1,431,390	5.56%
General Public	2,006,665	7.8%
Institutions	7,360,884	28.6%
Individual Insiders	14,926,367	58%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 376.6%.

Top Shareholders

Top 25 shareholders own 90.03% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
36.5%	Timothy Springer	9,385,399	€174.8m	8.22%	no data
19.7%	Murat Kalayoglu	5,057,682	€94.2m	43%	no data
11.1%	FMR LLC	2,851,830	€53.1m	460%	no data
4.07%	Schooner Century Fund Llc	1,047,594	€19.5m	1,920%	no data
2.45%	BioImpact Capital LLC	629,423	€11.7m	142%	2.05%
2.22%	Artal Group S.A.	572,236	€10.7m	87.9%	0.32%
1.65%	BlackRock, Inc.	423,466	€7.9m	3.89%	no data
1.6%	HBM Partners Ltd.	412,364	€7.7m	91.6%	0.85%
1.49%	Thirsty Brook 2010 Irrevocable Trust	383,796	€7.1m	0%	no data
1.46%	Citadel Advisors LLC	375,767	€7.0m	0%	0.01%
1.1%	JP Morgan Asset Management	283,796	€5.3m	0.98%	no data
1.01%	Michael Singer	259,416	€4.8m	-15.3%	no data
0.94%	The Vanguard Group, Inc.	243,089	€4.5m	2.72%	no data
0.78%	Great Point Partners, LLC	200,000	€3.7m	0%	1.67%
0.67%	Erste Asset Management GmbH	173,566	€3.2m	42%	0.03%
0.61%	State Street Global Advisors, Inc.	157,495	€2.9m	2.49%	no data
0.53%	Geode Capital Management, LLC	135,700	€2.5m	2.06%	no data
0.39%	Yale Investment Office	100,000	€1.9m	0%	68.46%
0.38%	Armistice Capital LLC	98,565	€1.8m	0%	0.04%
0.31%	Baharak Asefzadeh	78,634	€1.5m	0%	no data
0.29%	683 Capital Management, LLC	75,431	€1.4m	0%	0.15%
0.25%	Northern Trust Global Investments	63,115	€1.2m	104%	no data
0.2%	Ikarian Capital, LLC	52,193	€972.3k	-78.5%	0.3%
0.19%	Schonfeld Strategic Advisors LLC	50,000	€931.4k	-143%	0.01%
0.19%	Balyasny Asset Management L.P.	49,497	€922.1k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/02 17:56
End of Day Share Price	2025/01/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cartesian Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Julian Harrison	BTIG
John Newman	Canaccord Genuity
Kristen Kluska	Cantor Fitzgerald & Co.